Skip to main content
Fig. 2 | Biomarker Research

Fig. 2

From: EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

Fig. 2

Safety overview of emerging therapies. The AEs (grade ≥ 3) of poziotinib, mobocertinib, amivantamab, CLN-081and DZD9008 were 66, 69, 35, 44 and 39.2%, respectively. The TRAEs (grade ≥ 3) of poziotinib, mobocertinib, amivantamab, CLN-081and DZD9008 are 35%, 47, 16, 18 and 33.3%, respectively. Furmonertinib is relatively safe. AEs or TRAEs (grade ≥ 3) were not observed in the cohort

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us